ActivePhase 3Phase 4ACTRN12608000396325

Comparison of the efficacy of oxtyocin agonist to oxytocin in the prevention of postpartum hemorrhage (PPH) in women undergoing vaginal delivery

Sponsor

Dr Farouk

Enrollment

720 participants

Start Date

Dec 13, 2006

Study Type

Interventional

Conditions

vaginal delivery and blood loss Postpartum Hemorrhage

Summary

This study is intended to compare the efficacy and safety of an oxytocin analogue and oxytocin in the prevention of postpartum hemorrhage (massive bleeding after birth) in women undergoing vaginal delivery. Oxytocin and its analogue are drugs used to contract the uterus to prevent postpartum hemorrhage. We would like to compare the effect of the drugs to lower the need for additional intervention (additional massage or other uterotonic needed) in the prevention of PPH postpartum hemorrhage.

Eligibility

Sex: FemalesMin Age: 18 YearssMax Age: 40 Yearss

Plain Language Summary

Simplified for easier understanding

This study compares a new oxytocin-like drug to standard oxytocin for preventing heavy bleeding after vaginal delivery (postpartum haemorrhage). The medication is given right after the baby is born to help the uterus contract. It is for healthy women aged 18 to 40 having a vaginal delivery of a single baby, who have had between one and four previous deliveries.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

For the management of 3rd stage of labour at vaginal delivery, 100 microgram Intramuscular (IM) slow bolus injection of oxytocin agonist after infant is delivered